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Dear Editor,
Plexiform neurofibroma (PNF) is a particular sub-
type of benign nerve sheath tumors with a reticular 
growth pattern not respecting tissue borders and in-
volving several nerve branches or fascicles. It is most 
commonly reported in patients with neurofibromato-
sis type-1 (NF-1) and represents in up to 30% of NF-
1 patients (1,2). Other possible associations include 
schwannomatosis, multiple cutaneous schwanno-
mas syndrome, and rarely neurofibromatosis type-2 
(NF-2) (3).
PNF develops as a result of tumor proliferation 
to all parts of the peripheral nervous system. It may 
cause functional and cosmetic impairment, pain, and 
a certain risk of malignant transformation in internal 
organs in some critical cases (4,5). Malignant periph-
eral nerve sheath tumors occur in about 10% of NF-1 
patients (4,5). NF-1 is caused by mutations in the NF-1 
tumor-suppressor gene, which encodes a GTPase-Ac-
tivating Protein (GAP) that negatively regulates p21-
RasNF1 (6). These patients have a predisposition to 
develop both benign and malignant tumors (6).
Isolated or NF-1-associated cutaneous or superfi-
cial PNF, however, do not transform into their malig-
nant counterpart (1). 
We report an isolated case of a plexiform PNF in a 
16-year-old girl without NF-1.
A-16-year-old Caucasian woman presented with 
a slow-growing exophytic nodule on her right flank. 
The tumor was asymptomatic, and tumor removal 
was requested for esthetic reasons. The patient was 
otherwise healthy. Her family history was negative for 
hereditary disorders. She was taking no medications 
at the time.
On examination, a 1.8×1.6 cm large, slow-growing, 
and asymptomatic exophytic asymptomatic tumor 
was observed on the right flank (Figure 1). The prima-
ry suspicion was a complex nevus tumor type such 
as nevus sebaceous or nevus lipomatosus. The tumor 
was surgically removed, and the defect was closed by 
tissue expansion. Histology revealed a spindle-cell 
proliferation of S-100 positive cells without cellular 
Figure 2. Histopathology of an isolated plexiform neurofibroma; (a, b) hematoxylin and eosin (×2); (c) S100-staining (×2).
Figure 1. Nodular mass of an isolated plexiform neurofi-
broma on the flank.
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atypia and myxoid stroma (Figure 2). The diagnosis 
of PNF was thus established. Healing was uneventful. 
There were no clinical signs of NF-1 or NF-2.
We reported a case of PNF without NF-1 or NF-2. 
The diagnosis of an isolated PNF is a very rare event 
(7-10). In a large study from Lima lasting 33 years, 
only one isolated PNF not associated with NF-1 was 
observed. In this patient, PNF developed in the oral 
mucosa (7). An isolated PNF causing an auricular de-
formity has been previously observed in a 14-year-
old boy (8). In India, a 11-year-old girl with an isolated 
PNF of the tongue was reported (9). Isolated PNFs are 
not necessarily limited to children and adolescents 
but may also occur later in life (10). 
The gold standard of treatment is surgical inter-
vention. In case of unresectable and painful tumors, 
interferon alfa is a medical option (11). Other drugs 
are under evaluation, such as oral selumetinib, a se-
lective inhibitor of MAPK kinase 1 and 2, AZD8055, an 
ATP-competitive “active-site” mTOR inhibitor, or a Bro-
moDomain-containing protein 4-inhibitor (12,13).
In conclusion, isolated PNF is a very rare observa-
tion. In case of impairment, surgery – whenever pos-
sible – is the preferred treatment option (8).
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